LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 185

Search options

  1. Book ; Thesis: Autonomous contractile activity in bladder as a new concept in neuro-urology

    Gevaert, Thomas

    a study in rat and mouse

    (Acta biomedica Lovaniensia ; 394)

    2007  

    Author's details Thomas Gevaert
    Series title Acta biomedica Lovaniensia ; 394
    Collection
    Language English
    Size 212 S. : Ill., graph. Darst.
    Publisher Leuven Univ. Press
    Publishing place Leuven
    Publishing country Belgium
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Leuven, Univ. Diss
    Note Zsfassung in niederl. Sprache
    HBZ-ID HT015722034
    ISBN 90-5867-612-9 ; 978-90-5867-612-2
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Quantity of Immune Cells Predict Response to Immunotherapy in Cancer.

    Salgado, Roberto / Gevaert, Thomas

    EClinicalMedicine

    2021  Volume 41, Page(s) 101170

    Language English
    Publishing date 2021-10-23
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2021.101170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Heart failure with severely reduced ejection fraction after liver transplantation: a case report and review of the literature.

    Pint, Dorien / Gevaert, Andreas B / Vanwolleghem, Thomas / Chapelle, Thiery / Dams, Karolien

    Acta clinica Belgica

    2024  Volume 79, Issue 1, Page(s) 46–51

    Abstract: Background: Liver transplantation (LT) is a strenuous event for the cardiovascular system. Cardiovascular events (CVE), including heart failure (HF), arrhythmias and myocardial ischemia, are important causes of peri- and post-liver transplantation ... ...

    Abstract Background: Liver transplantation (LT) is a strenuous event for the cardiovascular system. Cardiovascular events (CVE), including heart failure (HF), arrhythmias and myocardial ischemia, are important causes of peri- and post-liver transplantation morbidity and mortality.
    Case presentation: We describe the case of a 45-year-old male patient who developed heart failure with severely reduced ejection fraction (HFrEF) after receiving liver transplantation (LT) for end-stage post-alcoholic liver cirrhosis. Preoperative transthoracic echocardiography (TTE) demonstrated borderline left ventricular ejection fraction (LVEF) of 50% and diastolic dysfunction grade 2. On coronary angiography, the patient had no coronary stenoses. Persistent vasopressor need, increasing creatinine levels and progressive pleural effusion characterized the early postoperative period. TTE on postoperative day 6 revealed a new finding of a markedly reduced LVEF of 15%, accompanied by a discrete increase in hs-TnI and CK-MB without electrocardiographic (ECG) ST-T abnormalities. LVEF did not recover completely (EF 45%) during follow-up. The patient had a sudden death 4.5 months post-liver transplantation.
    Conclusion: Our case demonstrates that the risk of post-LT systolic dysfunction is not excluded by preoperative resting examinations within normal range and highlights the need for preoperative cardiac stress assessment (e.g. dobutamine echocardiography or stress cardiac magnetic resonance imaging) before LT. In addition, patients on a liver-transplant waiting list with cardiac dysfunction should be followed by a multidisciplinary team including a dedicated cardiology team experienced in managing liver-related cardiac pathology.
    MeSH term(s) Male ; Humans ; Middle Aged ; Heart Failure/surgery ; Heart Failure/complications ; Stroke Volume ; Liver Transplantation/adverse effects ; Ventricular Function, Left ; Ventricular Dysfunction, Left ; Cardiomyopathies/complications ; Arrhythmias, Cardiac
    Language English
    Publishing date 2024-01-02
    Publishing country England
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 390201-8
    ISSN 2295-3337 ; 0001-5512 ; 1784-3286
    ISSN (online) 2295-3337
    ISSN 0001-5512 ; 1784-3286
    DOI 10.1080/17843286.2023.2278240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Quantity of Immune Cells Predict Response to Immunotherapy in Cancer

    Roberto Salgado / Thomas Gevaert

    EClinicalMedicine, Vol 41, Iss , Pp 101170- (2021)

    2021  

    Keywords Medicine (General) ; R5-920
    Language English
    Publishing date 2021-11-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Heart of lymphoma: a case report.

    Jacobs, Annemie / Gevaert, Thomas / Volders, Wim / De Cleen, Dieter / Van Kolen, Katrien / Cools, Frank / Hellemans, Steven

    Acta cardiologica

    2023  Volume 78, Issue 4, Page(s) 509–513

    MeSH term(s) Humans ; Heart ; Lymphoma/diagnosis ; Heart Neoplasms/diagnosis
    Language English
    Publishing date 2023-02-21
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 390197-x
    ISSN 1784-973X ; 0001-5385
    ISSN (online) 1784-973X
    ISSN 0001-5385
    DOI 10.1080/00015385.2023.2178095
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms.

    Giunchi, Francesca / Gevaert, Thomas / Scarpelli, Marina / Fiorentino, Michelangelo

    Current drug targets

    2020  Volume 21, Issue 13, Page(s) 1286–1292

    Abstract: The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used ...

    Abstract The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors.
    Language English
    Publishing date 2020-01-22
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 2064859-5
    ISSN 1873-5592 ; 1389-4501
    ISSN (online) 1873-5592
    ISSN 1389-4501
    DOI 10.2174/1389450121666200123124642
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.

    Gevaert, Thomas / Cimadamore, Alessia / Montironi, Rodolfo / Eckstein, Markus

    Current drug targets

    2020  Volume 22, Issue 2, Page(s) 162–170

    Abstract: Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of ... ...

    Abstract Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients, immunohistochemical PD-L1 testing is now required. Several emerging issues on antibodies, test platforms and scoring algorithms have raised concerns about the comparability and interchangeability between these assays. In this review, we have focused on the interchangeability of the used algorithms and assays for PD-L1 testing in urothelial carcinoma, on the predictive reliability of PD-L1 testing in urothelial carcinoma and the potential of other new and upcoming biomarkers.
    MeSH term(s) B7-H1 Antigen/analysis ; B7-H1 Antigen/antagonists & inhibitors ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/drug therapy ; Humans ; Reproducibility of Results ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/drug therapy
    Chemical Substances B7-H1 Antigen
    Language English
    Publishing date 2020-05-09
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 2064859-5
    ISSN 1873-5592 ; 1389-4501
    ISSN (online) 1873-5592
    ISSN 1389-4501
    DOI 10.2174/1389450121666200510015216
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: No survival difference between super extended and standard lymph node dissection at radical cystectomy: what can we learn from the first prospective randomized phase III trial?

    Muilwijk, Tim / Akand, Murat / Gevaert, Thomas / Joniau, Steven

    Translational andrology and urology

    2019  Volume 8, Issue Suppl 1, Page(s) S112–S115

    Language English
    Publishing date 2019-04-29
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2851630-8
    ISSN 2223-4691 ; 2223-4691 ; 2223-4683
    ISSN (online) 2223-4691
    ISSN 2223-4691 ; 2223-4683
    DOI 10.21037/tau.2018.12.09
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Machine Learning Pipeline for Predicting Bone Marrow Edema Along the Sacroiliac Joints on Magnetic Resonance Imaging.

    Roels, Joris / De Craemer, Ann-Sophie / Renson, Thomas / de Hooge, Manouk / Gevaert, Arne / Van Den Berghe, Thomas / Jans, Lennart / Herregods, Nele / Carron, Philippe / Van den Bosch, Filip / Saeys, Yvan / Elewaut, Dirk

    Arthritis & rheumatology (Hoboken, N.J.)

    2023  Volume 75, Issue 12, Page(s) 2169–2177

    Abstract: Objective: We aimed to develop and validate a fully automated machine learning (ML) algorithm that predicts bone marrow edema (BME) on a quadrant level in sacroiliac (SI) joint magnetic resonance imaging (MRI).: Methods: A computer vision workflow ... ...

    Abstract Objective: We aimed to develop and validate a fully automated machine learning (ML) algorithm that predicts bone marrow edema (BME) on a quadrant level in sacroiliac (SI) joint magnetic resonance imaging (MRI).
    Methods: A computer vision workflow automatically locates the SI joints, segments regions of interest (ilium and sacrum), performs objective quadrant extraction, and predicts presence of BME, suggestive of inflammatory lesions, on a quadrant level in semicoronal slices of T1/T2-weighted MRI scans. Ground truth was determined by consensus among human readers. The inflammation classifier was trained using a ResNet18 backbone and five-fold cross-validated on scans of patients with spondyloarthritis (SpA) (n = 279), postpartum individuals (n = 71), and healthy subjects (n = 114). Independent SpA patient MRI scans (n = 243) served as test data set. Patient-level predictions were derived from aggregating quadrant-level predictions, ie, at least one positive quadrant.
    Results: The algorithm automatically detects the SI joints with a precision of 98.4% and segments ilium/sacrum with an intersection over union of 85.6% and 67.9%, respectively. The inflammation classifier performed well in cross-validation: area under the curve (AUC) 94.5%, balanced accuracy (B-ACC) 80.5%, and F1 score 64.1%. In the test data set, AUC was 88.2%, B-ACC 72.1%, and F1 score 50.8%. On a patient level, the model achieved a B-ACC of 81.6% and 81.4% in the cross-validation and test data set, respectively.
    Conclusion: We propose a fully automated ML pipeline that enables objective and standardized evaluation of BME along the SI joints on MRI. This method has the potential to screen large numbers of patients with (suspected) SpA and is a step closer towards artificial intelligence-assisted diagnosis and follow-up.
    MeSH term(s) Female ; Humans ; Sacroiliac Joint/diagnostic imaging ; Sacroiliac Joint/pathology ; Bone Marrow/diagnostic imaging ; Bone Marrow/pathology ; Artificial Intelligence ; Spondylarthritis/pathology ; Bone Marrow Diseases/diagnostic imaging ; Bone Marrow Diseases/pathology ; Inflammation/pathology ; Magnetic Resonance Imaging/methods ; Edema/diagnostic imaging ; Edema/pathology ; Machine Learning ; Sacroiliitis/pathology
    Language English
    Publishing date 2023-11-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42650
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Collecting duct renal cell carcinoma: a single centre series and review of the literature.

    Vanderbruggen, Wies / Claessens, Marc / De Coninck, Vincent / Duchateau, Aline / Gevaert, Thomas / Joniau, Steven / Hente, Robert

    Central European journal of urology

    2022  Volume 75, Issue 3, Page(s) 252–256

    Abstract: Introduction: Collecting duct, or Bellini duct, renal cell carcinoma (CDRCC) is a rare tumour, comprising only 0.4-2% of all renal cell carcinoma. The goal of this study was to evaluate the cases in our institution and look at current available ... ...

    Abstract Introduction: Collecting duct, or Bellini duct, renal cell carcinoma (CDRCC) is a rare tumour, comprising only 0.4-2% of all renal cell carcinoma. The goal of this study was to evaluate the cases in our institution and look at current available literature.
    Material and methods: We searched all data on renal cell tumours in our institution between 2011 and 2021 and identified four cases with confirmed CDRCC pathology. Important features were listed and analysed. We also reviewed current available literature and compared it to our case series.
    Results: All cases were men with a median age of 63.5 years. All were symptomatic at presentation. Two patients presented with flank pain and two with gross haematuria. Three patients had stage IV disease at time of presentation and one stage III disease. All cases had clear Bellini duct renal cell carcinoma appearance on microscopy with infiltrative tubular architecture and high-grade nuclear features. Immunohistochemic (IHC) staining was performed for diagnostic confirmation. Three patients underwent radical nephrectomy and received adjuvant chemotherapy. One case had kidney biopsy for diagnostic confirmation and received first line chemotherapy. Immunotherapy or tyrosine kinase inhibitor (TKI) were started for second, third or fourth line of treatment. Median overall survival after diagnosis was 11 months.
    Conclusions: CDRCC is a rare subtype of renal cell carcinoma with poor prognosis, typically presenting in a more advanced or metastatic stage. Diagnosis can be challenging. Multimodality treatment should be considered using radical surgery and systemic treatment.
    Language English
    Publishing date 2022-09-06
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2672528-9
    ISSN 2080-4873 ; 2080-4806
    ISSN (online) 2080-4873
    ISSN 2080-4806
    DOI 10.5173/ceju.2022.0143
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top